Paper25566959
Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.
Greife A and 5 others. Tumour Biol, 2015. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation. Papers, record 25566959. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25566959
- Cell line
- BFTC-905-DOXO-II1 paper
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Source Cell lines
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antineoplastic | Major topic |
| Doxorubicin | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Biosynthetic Pathways | |
| Cell Line, Tumor | |
| Cell Survival | |
| Drug Synergism | |
| Humans | |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | |
| Inhibitory Concentration 50 | |
| Mevalonic Acid | |
| Simvastatin | |
| Transcriptome |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1822001 | The uptake and efflux of doxorubicin by a sensitive human bladder cancer cell line and its doxorubicin-resistant subline. | Sel Cancer Ther | 1991 | https://conductscience.org/library/papers/1822001 | PubMed |
| 2 | 9477189 | Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells. | Int J Urol | 1997 | https://conductscience.org/library/papers/9477189 | PubMed |
| 3 | 20477901 | The RNA binding protein Musashi1 regulates apoptosis, gene expression and stress granule formation in urothelial carcinoma cells. | J Cell Mol Med | 2011 | https://conductscience.org/library/papers/20477901 | PubMed |
| 4 | 20696928 | Dysregulation of the mevalonate pathway promotes transformation. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20696928 | PubMed |
| 5 | 12923562 | In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. | Gene Ther | 2003 | https://conductscience.org/library/papers/12923562 | PubMed |
| 6 | 18840072 | Molecular pathogenesis and diagnostics of bladder cancer. | Annu Rev Pathol | 2009 | https://conductscience.org/library/papers/18840072 | PubMed |
| 7 | 24582968 | Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. | Pharmacol Ther | 2014 | https://conductscience.org/library/papers/24582968 | PubMed |
| 8 | 8567404 | Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. | Jpn J Cancer Res | 1995 | https://conductscience.org/library/papers/8567404 | PubMed |
| 9 | 15161671 | Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. | Blood | 2004 | https://conductscience.org/library/papers/15161671 | PubMed |
| 10 | 19760159 | Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. | Invest New Drugs | 2010 | https://conductscience.org/library/papers/19760159 | PubMed |
| 11 | 23040256 | New therapeutic challenges in advanced bladder cancer. | Semin Oncol | 2012 | https://conductscience.org/library/papers/23040256 | PubMed |
| 12 | 23038228 | Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy. | Onkologie | 2012 | https://conductscience.org/library/papers/23038228 | PubMed |
| 13 | 14501774 | Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. | J Urol | 2003 | https://conductscience.org/library/papers/14501774 | PubMed |
| 14 | 22310279 | Targeting tumor cell metabolism with statins. | Oncogene | 2012 | https://conductscience.org/library/papers/22310279 | PubMed |
| 15 | 8712703 | Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. | Anticancer Res | 1996 | https://conductscience.org/library/papers/8712703 | PubMed |
| 16 | 21398618 | Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. | J Natl Cancer Inst | 2011 | https://conductscience.org/library/papers/21398618 | PubMed |
| 17 | 23395802 | Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. | J Urol | 2013 | https://conductscience.org/library/papers/23395802 | PubMed |
| 18 | 19508172 | Targeting the mevalonate pathway for improved anticancer therapy. | Curr Cancer Drug Targets | 2009 | https://conductscience.org/library/papers/19508172 | PubMed |
| 19 | 15818381 | Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin. | Cancer Gene Ther | 2005 | https://conductscience.org/library/papers/15818381 | PubMed |
| 20 | 8100862 | Evaluation of multiple drug resistance in human bladder cancer cell lines. | J Urol | 1993 | https://conductscience.org/library/papers/8100862 | PubMed |
Cited by20
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41226440 | The Managed Acquisition of Chemoresistance as an Informative Tool for Tumor Research. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41226440 | PubMed |
| 40947699 | The Impact of IGFBP6 Knockdown on Cholesterol Metabolism in Breast Cancer Cells. | Curr Med Chem | 2026 | https://conductscience.org/library/papers/40947699 | PubMed |
| 40916434 | Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting. | Protein Pept Lett | 2025 | https://conductscience.org/library/papers/40916434 | PubMed |
| 40353763 | Repurposing Amiodarone for Bladder Cancer Treatment. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/40353763 | PubMed |
| 39838687 | The Expression of the LDLR, LDLRAP1, and PCSK9 Genes has Prognostic Significance in Triple-negative Breast Cancer. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/39838687 | PubMed |
| 39521858 | Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization. | Commun Biol | 2024 | https://conductscience.org/library/papers/39521858 | PubMed |
| 38677545 | Abnormal changes in metabolites caused by m6A methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application. | J Adv Res | 2025 | https://conductscience.org/library/papers/38677545 | PubMed |
| 38617549 | Cholesterol metabolism in tumor microenvironment: cancer hallmarks and therapeutic opportunities. | Int J Biol Sci | 2024 | https://conductscience.org/library/papers/38617549 | PubMed |
| 38255214 | 2-Aminoethyl Dihydrogen Phosphate (2-AEH2P) Associated with Cell Metabolism-Modulating Drugs Presents a Synergistic and Pro-Apoptotic Effect in an In Vitro Model of the Ascitic Ehrlich Tumor. | Biomedicines | 2024 | https://conductscience.org/library/papers/38255214 | PubMed |
| 37175843 | MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37175843 | PubMed |
| 36481936 | Atorvastatin improves cisplatin sensitivity through modulation of cholesteryl ester homeostasis in breast cancer cells. | Discov Oncol | 2022 | https://conductscience.org/library/papers/36481936 | PubMed |
| 35719918 | Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. | Front Oncol | 2022 | https://conductscience.org/library/papers/35719918 | PubMed |
| 35093030 | Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDFT1: a review. | Cell Mol Biol Lett | 2022 | https://conductscience.org/library/papers/35093030 | PubMed |
| 34065757 | Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance. | Pharmaceuticals (Basel) | 2021 | https://conductscience.org/library/papers/34065757 | PubMed |
| 32326336 | Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32326336 | PubMed |
| 31286834 | MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways. | Cell Cycle | 2019 | https://conductscience.org/library/papers/31286834 | PubMed |
| 29876015 | Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins. | Oncotarget | 2018 | https://conductscience.org/library/papers/29876015 | PubMed |
| 28373964 | Altered Mitochondrial Signalling and Metabolism in Cancer. | Front Oncol | 2017 | https://conductscience.org/library/papers/28373964 | PubMed |
| 27779188 | Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway. | Sci Rep | 2016 | https://conductscience.org/library/papers/27779188 | PubMed |
| 26698156 | Increased lanosterol turnover: a metabolic burden for daunorubicin-resistant leukemia cells. | Med Oncol | 2016 | https://conductscience.org/library/papers/26698156 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CASP3 | 836 | PubTator's text mining | https://conductscience.org/library/genes/836 | NCBI Gene |
| CASP7 | 840 | PubTator's text mining | https://conductscience.org/library/genes/840 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25566959
GET https://conductscience.org/api/papers/v1/25566959/references?page=2